ABIONYX PHARMA SA (ABNX.PA) Stock Overview
EPA:ABNX - FR0012616852 - Common Stock
ABNX.PA Key Statistics, Chart & Performance
The current stock price of ABNX.PA is 3.67 EUR. In the past month the price increased by 131.4%. In the past year, price increased by 184.5%.
ABNX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 20 | 319.75B | ||
| 1ABBV.MI | ABBVIE INC | 19.65 | 314.09B | ||
| AMG.DE | AMGEN INC | 12.91 | 129.61B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 14.83 | 121.80B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.81 | 121.61B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 23.41 | 86.90B | ||
| ARGX.BR | ARGENX SE | 86.58 | 39.16B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 23.37B | ||
| IDP.DE | BIOGEN INC | 8.88 | 17.81B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.26B | ||
| 0QF.DE | MODERNA INC | N/A | 8.25B | ||
| 1EXAS.MI | EXACT SCIENCES CORP | N/A | 7.29B |
Related stock screener links
About ABNX.PA
Company Profile
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 51 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Company Info
ABIONYX PHARMA SA
Bat. D 33-43 Avenue Georges Pompidou
Balma OCCITANIE FR
Employees: 51
Phone: 33562249706
ABIONYX PHARMA SA / ABNX.PA FAQ
What is the stock price of ABIONYX PHARMA SA today?
The current stock price of ABNX.PA is 3.67 EUR. The price decreased by -2.52% in the last trading session.
What is the ticker symbol for ABIONYX PHARMA SA stock?
The exchange symbol of ABIONYX PHARMA SA is ABNX and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ABNX.PA stock listed?
ABNX.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for ABIONYX PHARMA SA stock?
8 analysts have analysed ABNX.PA and the average price target is 10.97 EUR. This implies a price increase of 198.77% is expected in the next year compared to the current price of 3.67. Check the ABIONYX PHARMA SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABIONYX PHARMA SA worth?
ABIONYX PHARMA SA (ABNX.PA) has a market capitalization of 128.19M EUR. This makes ABNX.PA a Micro Cap stock.
How many employees does ABIONYX PHARMA SA have?
ABIONYX PHARMA SA (ABNX.PA) currently has 51 employees.
What are the support and resistance levels for ABIONYX PHARMA SA (ABNX.PA) stock?
ABIONYX PHARMA SA (ABNX.PA) has a support level at 1.94. Check the full technical report for a detailed analysis of ABNX.PA support and resistance levels.
Is ABIONYX PHARMA SA (ABNX.PA) expected to grow?
The Revenue of ABIONYX PHARMA SA (ABNX.PA) is expected to grow by 4.35% in the next year. Check the estimates tab for more information on the ABNX.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABIONYX PHARMA SA (ABNX.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABNX.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABNX.PA, evaluating the profitability, health, valuation and growth aspects
- ABIONYX PHARMA SA (ABNX.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABIONYX PHARMA SA (ABNX.PA) Sales and EPS estimates to see what analysts future expectations are.
- ABIONYX PHARMA SA (ABNX.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABIONYX PHARMA SA (ABNX.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABIONYX PHARMA SA (ABNX.PA) Stock Chart to make your own analysis
- ABIONYX PHARMA SA (ABNX.PA) Latest news and press-releases to stay up to date.
Does ABIONYX PHARMA SA (ABNX.PA) stock pay dividends?
ABNX.PA does not pay a dividend.
When does ABIONYX PHARMA SA (ABNX.PA) report earnings?
ABIONYX PHARMA SA (ABNX.PA) will report earnings on 2025-09-25.
What is the Price/Earnings (PE) ratio of ABIONYX PHARMA SA (ABNX.PA)?
ABIONYX PHARMA SA (ABNX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
ABNX.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ABNX.PA. When comparing the yearly performance of all stocks, ABNX.PA is one of the better performing stocks in the market, outperforming 99.35% of all stocks.
ABNX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABNX.PA. The financial health of ABNX.PA is average, but there are quite some concerns on its profitability.
ABNX.PA Financial Highlights
Over the last trailing twelve months ABNX.PA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS decreased by -7.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.35% | ||
| ROE | -58.3% | ||
| Debt/Equity | 0.25 |
ABNX.PA Forecast & Estimates
8 analysts have analysed ABNX.PA and the average price target is 10.97 EUR. This implies a price increase of 198.77% is expected in the next year compared to the current price of 3.67.
For the next year, analysts expect an EPS growth of -65.62% and a revenue growth 4.35% for ABNX.PA